首页> 美国卫生研究院文献>Journal of Radiation Research >Survival outcome of cervical cancer patients treated by image-guided brachytherapy: a ‘real world’ single center experience in Thailand from 2008 to 2018
【2h】

Survival outcome of cervical cancer patients treated by image-guided brachytherapy: a ‘real world’ single center experience in Thailand from 2008 to 2018

机译:接受图像引导近距离放射治疗的宫颈癌患者的生存结果:2008 年至 2018 年泰国的真实世界单中心体验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of our study was to evaluate the survival outcome of cervical cancer patients treated using image-guided brachytherapy (IGBT). From 2008 to 2018, 341 patients with cervical cancer were treated by radical radiotherapy. IGBT (by computed tomography [CT] or transabdominal ultrasound [TAUS]) was used to treat all of these patients. The characteristic data and patient status after treatment were recorded. All data were evaluated for survival outcome analysis. From a total of 341 patients, 295 patients were analyzed and 46 patients were excluded due to data missing in the survival outcomes. At the median follow-up time of 48 months (IQR 30–80 months), The 4-year local control, progression-free survival and overall survival rates were 89.5%, 74.9% and 69.1%, respectively. For overall survival, the size (> 5 cm), pathology (non-SCCA), stage (stage III–IV by FIGO 2009), lymph node (LN) (presented) and overall treatment time (OTT) (> 56 days) showed statistical significance in univariate analysis while non-SCCA pathology, advanced stage, presented LN and longer OTT showed statistical significance in multivariate analysis. In conclusion, our analysis reports a 4-year overall survival rate of 69.1%. Non-SCCA pathology, advanced stage disease, LN presence and longer OTT showed worse prognostic factors in multivariate analysis.
机译:我们研究的目的是评估使用图像引导近距离放射治疗 (IGBT) 治疗的宫颈癌患者的生存结果。2008 年至 2018 年,341 例宫颈癌患者接受了根治性放疗。IGBT (通过计算机断层扫描 [CT] 或经腹超声 [TAUS])用于治疗所有这些患者。记录特征资料和治疗后患者状态。评估所有数据用于生存结局分析。在总共 341 例患者中,分析了 295 例患者,46 例患者因生存结局数据缺失而被排除在外。中位随访时间为 48 个月 (IQR 30-80 个月),4 年局部对照、无进展生存率和总生存率分别为 89.5% 、 74.9% 和 69.1%。对于总生存期,大小 (> 5 cm)、病理学 (非 SCCA)、分期 (FIGO 2009 的 III-IV 期)、淋巴结 (LN) (呈现) 和总治疗时间 (OTT) (> 56 天) 在单变量分析中表现出统计学意义,而非 SCCA 病理、晚期、呈现 LN 和更长的 OTT 在多变量分析中表现出统计学意义。总之,我们的分析报告了 4 年总生存率为 69.1%。非 SCCA 病理、晚期疾病、LN 存在和较长的 OTT 在多变量分析中显示更差的预后因素。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号